Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

It recently reported strong phase 3 results for an investigational eczema treatment, rocatinlimab. A strong lineup and ...

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis The IGNITE study, which evaluated two dose strengths of ...

32.8% of rocatinlimab-treated patients achieved the co-primary endpoint of EASI 75 by week 24. 19.3% reached the other co-primary endpoint, defined as a validated IGA-AD score of 0 or 1 by week 24.

The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...